| Drug General Information |
| Drug ID |
D0U3XL
|
| Former ID |
DIB000578
|
| Drug Name |
JNJ-26483327
|
| Synonyms |
MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
|---|
| Company |
Johnson & Johnson
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
c12c(cc3c(c1)c(ncn3)Nc1cc(ccc1CN(CCCCCO2)C)Br)OC
|
| CAS Number |
CAS 807640-87-5
|
| Target and Pathway |
| Target(s) |
Lyn tyrosine kinase |
Target Info |
Inhibitor |
[2]
|
|---|
| Epidermal growth factor receptor |
Target Info |
Inhibitor |
[2]
|
| Vascular endothelial growth factor receptor 3 |
Target Info |
Inhibitor |
[2]
|
| Fyn tyrosine kinase |
Target Info |
Inhibitor |
[3]
|
| Receptor protein-tyrosine kinase erbB-2 |
Target Info |
Inhibitor |
[2]
|
| Lck tyrosine kinase |
Target Info |
Inhibitor |
[2]
|
| Proto-oncogene tyrosine-protein kinase Yes |
Target Info |
Inhibitor |
[2]
|
| Receptor protein-tyrosine kinase erbB-4 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
NF-kappa B signaling pathway
|
|
Platelet activation
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Long-term depression
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesishsa04010:MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Dorso-ventral axis formation
|
|
Focal adhesion
|
|
Adherens junction
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
Hepatitis C
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04014:Ras signaling pathway
|
|
Focal adhesionhsa04071:Sphingolipid signaling pathway
|
|
Axon guidance
|
|
Osteoclast differentiation
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
Cholinergic synapse
|
|
Prion diseases
|
|
Pathogenic Escherichia coli infection
|
|
Measles
|
|
Viral myocarditishsa04012:ErbB signaling pathway
|
|
Central carbon metabolism in cancerhsa04064:NF-kappa B signaling pathway
|
|
HTLV-I infection
|
|
Primary immunodeficiencyhsa04520:Adherens junction
|
|
Tight junctionhsa04012:ErbB signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_16:IL4 Signaling Pathway
|
|
EGFR1 Signaling PathwayNetPath_9:TNFalpha Signaling PathwayNetPath_23:TSH Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
TGF_beta_Receptor Signaling PathwayNetPath_11:TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
IL2 Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
|
PANTHER Pathway
|
B cell activation
|
|
Parkinson disease
|
|
CCKR signaling map STP00012:Cadherin signaling pathway
|
|
EGF receptor signaling pathwayP00007:Axon guidance mediated by semaphorins
|
|
Cadherin signaling pathway
|
|
Integrin signalling pathway
|
|
Parkinson diseaseP00012:Cadherin signaling pathway
|
|
EGF receptor signaling pathwayP00049:Parkinson disease
|
|
T cell activationP00012:Cadherin signaling pathway
|
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
|
|
EGF receptor signaling pathway
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
LPA receptor mediated events
|
|
GMCSF-mediated signaling events
|
|
Glypican 1 network
|
|
Signaling events mediated by PTP1B
|
|
Regulation of p38-alpha and p38-beta
|
|
Thromboxane A2 receptor signaling
|
|
CXCR4-mediated signaling events
|
|
IL5-mediated signaling events
|
|
Class I PI3K signaling events
|
|
amb2 Integrin signaling
|
|
EPHA forward signaling
|
|
PDGFR-beta signaling pathway
|
|
IL8- and CXCR2-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
IL8- and CXCR1-mediated signaling events
|
|
Ephrin B reverse signaling
|
|
Alpha-synuclein signalinglysophospholipid_pathway:LPA receptor mediated events
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
Regulation of Telomerase
|
|
EGF receptor (ErbB1) signaling pathway
|
|
EGFR-dependent Endothelin signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
E-cadherin signaling in keratinocytes
|
|
ErbB receptor signaling network
|
|
Internalization of ErbB1
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
Syndecan-3-mediated signaling eventsvegf_vegfr_pathway:VEGF and VEGFR signaling network
|
|
VEGFR3 signaling in lymphatic endotheliumfcer1pathway:Fc-epsilon receptor I signaling in mast cells
|
|
ErbB4 signaling events
|
|
TCR signaling in naï
|
|
Ephrin A reverse signaling
|
|
Reelin signaling pathway
|
|
TCR signaling in naï
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Netrin-mediated signaling events
|
|
IL2-mediated signaling events
|
|
Nephrin/Neph1 signaling in the kidney podocyte
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Syndecan-3-mediated signaling events
|
|
Alpha-synuclein signaling
|
|
Signaling events mediated by focal adhesion kinaseerbb4_pathway:ErbB4 signaling events
|
|
ErbB2/ErbB3 signaling events
|
|
Validated targets of C-MYC transcriptional repressionnfkappabatypicalpathway:Atypical NF-kappaB pathway
|
|
IL12-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5
|
|
Alpha-synuclein signalingwnt_noncanonical_pathway:Noncanonical Wnt signaling pathway
|
|
CDC42 signaling events
|
|
Signaling events mediated by focal adhesion kinase
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast CellsPW000453:Fc Epsilon Receptor I Signaling in Mast CellsPW000168:Phosphatidylinositol Phosphate Metabolism
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
Regulation of KIT signaling
|
|
Cell surface interactions at the vascular wall
|
|
FCGR activation
|
|
PECAM1 interactions
|
|
Fc epsilon receptor (FCERI) signaling
|
|
EPH-Ephrin signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
FCERI mediated MAPK activation
|
|
FCERI mediated Ca+2 mobilization
|
|
FCERI mediated NF-kB activation
|
|
CD28 co-stimulation
|
|
CTLA4 inhibitory signaling
|
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
EPH-ephrin mediated repulsion of cells
|
|
Dectin-2 family
|
|
CD209 (DC-SIGN) signaling
|
|
Platelet Adhesion to exposed collagen
|
|
Regulation of signaling by CBL
|
|
Growth hormone receptor signaling
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in EGFR signaling
|
|
GAB1 signalosome
|
|
SHC1 events in EGFR signaling
|
|
EGFR downregulation
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
EGFR Transactivation by Gastrin
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Constitutive Signaling by EGFRvIII
|
|
RAF/MAP kinase cascadeR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerizationR-HSA-114604:GPVI-mediated activation cascade
|
|
DAP12 signaling
|
|
Nephrin interactions
|
|
NCAM signaling for neurite out-growth
|
|
CD28 dependent PI3K/Akt signaling
|
|
CD28 dependent Vav1 pathway
|
|
CRMPs in Sema3A signaling
|
|
DCC mediated attractive signaling
|
|
Netrin mediated repulsion signals
|
|
VEGFA-VEGFR2 Pathway
|
|
RAF/MAP kinase cascade
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-1250196:SHC1 events in ERBB2 signaling
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
RAF/MAP kinase cascadeR-HSA-114604:GPVI-mediated activation cascade
|
|
Phosphorylation of CD3 and TCR zeta chains
|
|
Translocation of ZAP-70 to Immunological synapse
|
|
Generation of second messenger molecules
|
|
PD-1 signaling
|
|
Interleukin-2 signalingR-HSA-1433559:Regulation of KIT signaling
|
|
WikiPathways
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Signaling by SCF-KIT
|
|
Growth hormone receptor signaling
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Platelet Adhesion to exposed collagen
|
|
GPVI-mediated activation cascade
|
|
Costimulation by the CD28 family
|
|
Cell surface interactions at the vascular wall
|
|
IL-5 Signaling PathwayWP673:ErbB Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
Focal Adhesion
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
|
Bladder Cancer
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Signaling by ERBB4
|
|
Signaling by ERBB2
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
PIP3 activates AKT signaling
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Aryl Hydrocarbon Receptor
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Gastric cancer network 2
|
|
AGE/RAGE pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by EGFR
|
|
L1CAM interactionsWP1919:Signaling by VEGFWP69:TCR Signaling Pathway
|
|
Interferon type I signaling pathways
|
|
IL-2 Signaling Pathway
|
|
Ectoderm Differentiation
|
|
DAP12 interactions
|
|
Host Interactions of HIV factors
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
Primary Focal Segmental Glomerulosclerosis FSGS
|
|
BDNF signaling pathway
|
|
Interleukin-11 Signaling Pathway
|
|
Pathogenic Escherichia coli infection
|
|
IL-7 Signaling Pathway
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Netrin-1 signaling
|
|
Nephrin interactions
|
|
NCAM signaling for neurite out-growth
|
|
Integrin-mediated Cell Adhesion
|
|
Cell surface interactions at the vascular wallWP710:DNA Damage Response (only ATM dependent)
|
|
ErbB Signaling Pathway
|
|
Semaphorin interactionsWP61:Notch Signaling Pathway
|
|
Inflammatory Response Pathway
|
|
TCR signaling
|
|
Costimulation by the CD28 familyWP2713:Signaling by SCF-KIT
|
|
Costimulation by the CD28 familyWP673:ErbB Signaling Pathway
|
|
EV release from cardiac cells and their functional effects
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health. |
|---|
| REF 2 | National Cancer Institute Drug Dictionary (drug id 596693). |
|---|
| REF 3 | National Cancer Institute Drug Dictionary (drug id 596693). |
|---|
